Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senior Vice President of Clinical DevelopmentGlobeNewsWire • 02/17/21
Cue Biopharma: CUE-101's Phase 1 Promising Progress, 1 New IND Expected, Funding Until Q2 2022Seeking Alpha • 01/07/21
Do Options Traders Know Something About Cue Biopharma (CUE) Stock We Don't?Zacks Investment Research • 12/07/20
Cue Biopharma to Present at the Piper Sandler 32nd Annual Healthcare ConferenceGlobeNewsWire • 11/23/20
Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with MerckGlobeNewsWire • 11/19/20
Cue Biopharma Reports Third Quarter 2020 Results and CUE-101 Phase 1 Dose Escalation Trial UpdatesGlobeNewsWire • 11/17/20
Cue Biopharma Announces Presentations Highlighting Clinical Progress of CUE-101, Pipeline Progress of CUE-100 Series Immuno-STATs and Immuno-STAT Data for Infectious Disease Applications at the Society for Immunotherapy of Cancer's (SITC) 35th AnniversaryGlobeNewsWire • 11/09/20
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual MeetingGlobeNewsWire • 10/19/20
Cue Biopharma Announces Nature Methods Publication of Preclinical Data Showing Tumor Penetration and Antigen-Specific T Cell Engagement with Immuno-STAT Based Protein ScaffoldsGlobeNewsWire • 09/15/20
Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 09/01/20
Cue Biopharma Reports Second Quarter 2020 Results and CUE-101 Phase 1 Dose Escalation Trial UpdatesGlobeNewsWire • 08/31/20
Cue Biopharma to Present at the 16th Annual PEGS Boston Essential Protein Engineering & Cell Therapy SummitGlobeNewsWire • 08/24/20
Cue Biopharma, Inc. (CUE) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 08/06/20
Cue Biopharma Begins Dosing Cohort 5 in an Ongoing Phase 1 Monotherapy Trial of CUE-101 in HPV+ Recurrent/Metastatic Head and Neck CancerGlobeNewsWire • 07/28/20
Cue Biopharma Announces PLOS One Publication Demonstrating the Generation and Evaluation of Novel Molecules with Directed Mutations within the B7 SuperfamilyGlobeNewsWire • 07/08/20
Cue Biopharma Provides Update on Ongoing Phase 1 Trial Evaluating CUE-101 in Recurrent/Metastatic Head and Neck CancerGlobeNewsWire • 06/15/20
Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/20/20
Cue Biopharma Reports First Quarter 2020 Results, Updates of CUE-101 Phase 1 Dose Escalation Study and Recent Business HighlightsGlobeNewsWire • 05/19/20